A Ardizzoni
Overview
Explore the profile of A Ardizzoni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
2004
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Di Federico A, Hong L, Elkrief A, Thummalapalli R, Cooper A, Ricciuti B, et al.
Ann Oncol
. 2024 Dec;
36(3):297-308.
PMID: 39637943
Background: Approximately 10% of lung adenocarcinomas (LUADs) have mucinous histology (LUAD), which is associated with a light/absent smoking history and a high prevalence of KRAS mutations. We sought to characterize...
2.
Pizzutilo E, Agostara A, Oresti S, Signorelli D, Stabile S, Lauricella C, et al.
ESMO Open
. 2024 Jun;
9(6):103592.
PMID: 38878323
Background: Osimertinib represents the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC) harboring classical epidermal growth factor receptor (EGFR) mutations, constituting 80%-90% of all EGFR alterations....
3.
Brocchi S, Parmeggiani A, Gaudiano C, Balacchi C, Renzulli M, Brandi N, et al.
Acta Gastroenterol Belg
. 2021 Oct;
84(3):497-499.
PMID: 34599575
Pneumatosis Intestinalis (PI) is a rare radiological finding defined as the presence of extra-luminal gas within the intestinal wall. Several anti-tumor drugs can induce a damage of the gastrointestinal walls...
4.
Apolone G, Ardizzoni A, Biondi A, Bortolami A, Cardone C, Ciniselli C, et al.
ESMO Open
. 2021 Aug;
6(4):100227.
PMID: 34352703
Background: With the rapid development of innovative anticancer treatments, the optimization of tools able to accelerate the access of new drugs to the market by the regulatory authority is a...
5.
Tarricone R, Listorti E, Tozzi V, Torbica A, Banks H, Ghislandi S, et al.
J Cancer Policy
. 2021 Jul;
29:100297.
PMID: 34316437
Policymakers everywhere struggle to introduce therapeutic innovation while controlling costs, a particular challenge for the universal Italian National Healthcare System (SSN), which spends only 8.8% of GDP to care for...
6.
Dingemans A, Fruh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks L, et al.
Ann Oncol
. 2021 Apr;
32(7):839-853.
PMID: 33864941
No abstract available.
7.
Lo Preiato V, Salvagni S, Ricci C, Ardizzoni A, Pagotto U, Pelusi C
Rev Endocr Metab Disord
. 2021 Jan;
22(2):337-349.
PMID: 33409866
Immune Check-Point Inhibitors (CPIs) have improved long-term patients' outcomes in several advanced cancers. Diabetes mellitus induced by CPIs (CPI-DM) is considered the second most frequent endocrine CPIs' side effects with...
8.
Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, et al.
ESMO Open
. 2021 Jan;
6(1):100019.
PMID: 33399082
Background: The combination of a microtubule inhibitor (eribulin) with a nucleoside analog (gemcitabine) may synergistically induce tumor cell death, particularly in triple negative breast cancer (TNBC) characterized by high cell...
9.
Ghedini P, Bossert I, Zanoni L, Ceci F, Graziani T, Castellucci P, et al.
Eur J Nucl Med Mol Imaging
. 2017 Dec;
45(5):751-758.
PMID: 29192364
Aim: During our daily clinical practice using 11C-Choline PET/CT for restaging patients affected by relapsing prostate cancer (rPCa) we noticed an unusual but significant occurrence of hypodense hepatic lesions with...
10.
Gelsomino F, Fiorentino M, Zompatori M, Poerio A, Melotti B, Sperandi F, et al.
Ann Oncol
. 2017 Nov;
29(1):284-286.
PMID: 29106493
No abstract available.